NSF
Basic information
Region (hg38): 17:46590669-46757679
Links
Phenotypes
GenCC
Source:
- developmental and epileptic encephalopathy 96 (Limited), mode of inheritance: AD
- developmental and epileptic encephalopathy 96 (Limited), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NSF gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 4 | |||||
missense | 11 | 15 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 2 | 12 | 6 | 0 |
Variants in NSF
This is a list of pathogenic ClinVar variants found in the NSF region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-46692908-T-A | Likely benign (Jun 01, 2022) | |||
17-46692988-C-T | not specified | Uncertain significance (Jan 06, 2023) | ||
17-46692996-C-T | not specified | Uncertain significance (Mar 22, 2023) | ||
17-46693035-G-T | Developmental and epileptic encephalopathy 96 | Uncertain significance (Mar 06, 2023) | ||
17-46694534-G-A | not specified | Uncertain significance (Aug 26, 2022) | ||
17-46694563-C-T | Likely benign (Nov 01, 2024) | |||
17-46694577-C-T | not provided (-) | |||
17-46694579-G-A | Likely benign (Dec 01, 2022) | |||
17-46694584-G-A | Likely benign (Jul 01, 2023) | |||
17-46694643-C-A | not specified | Uncertain significance (Jul 09, 2024) | ||
17-46694647-G-A | Developmental and epileptic encephalopathy 96 | Uncertain significance (Oct 25, 2021) | ||
17-46694654-C-T | not specified | Uncertain significance (Sep 24, 2024) | ||
17-46704759-G-A | Developmental and epileptic encephalopathy 96 | Pathogenic (May 28, 2021) | ||
17-46711008-G-A | Likely benign (Dec 01, 2023) | |||
17-46711081-A-ACAG | Developmental and epileptic encephalopathy 96 | Uncertain significance (Jun 24, 2022) | ||
17-46711107-G-A | not specified | Uncertain significance (Jun 11, 2024) | ||
17-46713913-C-G | Developmental and epileptic encephalopathy 96 | Likely pathogenic (Jul 24, 2023) | ||
17-46713913-C-T | Developmental and epileptic encephalopathy 96 | Pathogenic/Likely pathogenic (Nov 10, 2023) | ||
17-46713956-T-C | Benign/Likely benign (Jul 01, 2023) | |||
17-46726601-T-C | not specified | Uncertain significance (Jun 18, 2024) | ||
17-46726612-C-T | Uncertain significance (May 01, 2022) | |||
17-46728908-G-A | not specified | Uncertain significance (Dec 10, 2024) | ||
17-46749801-C-G | Uncertain significance (Aug 01, 2022) | |||
17-46749873-T-C | not specified | Uncertain significance (Nov 30, 2022) | ||
17-46751530-C-T | not specified | Uncertain significance (Oct 12, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NSF | protein_coding | protein_coding | ENST00000398238 | 21 | 166796 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0183 | 0.981 | 124780 | 0 | 10 | 124790 | 0.0000401 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.58 | 107 | 213 | 0.502 | 0.0000112 | 4914 |
Missense in Polyphen | 22 | 75.477 | 0.29148 | 1668 | ||
Synonymous | 1.65 | 57 | 75.2 | 0.758 | 0.00000414 | 1376 |
Loss of Function | 2.93 | 7 | 21.8 | 0.321 | 0.00000121 | 505 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000223 | 0.000223 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000536 | 0.0000530 |
Middle Eastern | 0.000223 | 0.000223 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Required for vesicle-mediated transport. Catalyzes the fusion of transport vesicles within the Golgi cisternae. Is also required for transport from the endoplasmic reticulum to the Golgi stack. Seems to function as a fusion protein required for the delivery of cargo proteins to all compartments of the Golgi stack independent of vesicle origin. Interaction with AMPAR subunit GRIA2 leads to influence GRIA2 membrane cycling (By similarity). {ECO:0000250}.;
- Pathway
- Synaptic vesicle cycle - Homo sapiens (human);GABAergic synapse - Homo sapiens (human);Vasopressin-regulated water reabsorption - Homo sapiens (human);Synaptic Vesicle Pathway;Brain-Derived Neurotrophic Factor (BDNF) signaling pathway;Vesicle-mediated transport;gamma-aminobutyric acid receptor life cycle pathway;Membrane Trafficking;Post-translational protein modification;Metabolism of proteins;Neuronal System;BDNF;Transport to the Golgi and subsequent modification;Asparagine N-linked glycosylation;COPI-dependent Golgi-to-ER retrograde traffic;Golgi-to-ER retrograde transport;Trafficking of GluR2-containing AMPA receptors;Trafficking of AMPA receptors;Intra-Golgi traffic;Glutamate binding, activation of AMPA receptors and synaptic plasticity;COPI-mediated anterograde transport;Neurotransmitter receptors and postsynaptic signal transmission;Transmission across Chemical Synapses;COPII-mediated vesicle transport;ER to Golgi Anterograde Transport;Retrograde transport at the Trans-Golgi-Network;Intra-Golgi and retrograde Golgi-to-ER traffic
(Consensus)
Recessive Scores
- pRec
- 0.300
Haploinsufficiency Scores
- pHI
- 0.544
- hipred
- Y
- hipred_score
- 0.819
- ghis
- 0.666
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.570
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nsf
- Phenotype
- homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); pigmentation phenotype;
Zebrafish Information Network
- Gene name
- nsfb
- Affected structure
- pigment cell
- Phenotype tag
- abnormal
- Phenotype quality
- quality
Gene ontology
- Biological process
- positive regulation of receptor recycling;potassium ion transport;intracellular protein transport;exocytosis;endoplasmic reticulum to Golgi vesicle-mediated transport;retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum;vesicle-mediated transport;regulation of exocytosis;SNARE complex disassembly;Golgi to plasma membrane protein transport;plasma membrane fusion;positive regulation of protein catabolic process;COPII vesicle coating;Golgi vesicle docking
- Cellular component
- Golgi membrane;lysosomal membrane;Golgi stack;cytosol;plasma membrane;postsynaptic density;dendritic shaft;myelin sheath
- Molecular function
- SNARE binding;protein binding;ATP binding;ATPase activity;syntaxin-1 binding;Rab GTPase binding;protein kinase binding;PDZ domain binding;ionotropic glutamate receptor binding;ATPase activity, coupled;protein-containing complex binding;metal ion binding